Sponsors (4)
The bill strengthens drug supply resilience and emergency response by funding reserves and boosting domestic manufacturing, but it requires substantial federal spending and may disrupt some manufacturers and competition while still permitting some foreign reliance.
Patients with chronic conditions and hospitals/health systems would face fewer drug shortages because awarded entities must hold six-month (or Secretary‑approved) reserves of APIs and finished products.
Federal emergency response capacity would improve because the Secretary could direct production, allocate API reserves, and require transfers between manufacturers during public health emergencies.
Domestic manufacturing and surge capacity would increase by prioritizing awards to domestic establishments and allowing funding for facility construction and renovation.
Taxpayers would likely bear increased federal costs because the program is authorized up to $500 million for FY2026 and funds can support construction, manufacturing, and inventories.
Some existing drug makers and small manufacturers could face operational disruption from forced transfers of API stock or production directives, affecting their commercial plans and cash flow.
Manufacturers that fail to meet eligibility criteria (GMP, domestic capacity, surge capacity) could be excluded, potentially reducing competition and raising prices for some products.
Based on analysis of 2 sections of legislative text.
Requires HHS to fund eligible entities to maintain rolling reserves (typically six months) of critical drugs and APIs and allows HHS to direct production and transfers during shortages or emergencies.
Introduced June 12, 2025 by Gary C. Peters · Last progress June 12, 2025
Requires the HHS Secretary to fund and contract with eligible entities to create and maintain a rolling reserve of critical drugs and their active pharmaceutical ingredients (APIs) that have vulnerable supply chains. Covered entities must hold (typically) a six-month supply of both API and finished product in qualified U.S. or OECD-registered facilities, keep those reserves recently manufactured and replenished, and accept HHS direction to produce or transfer supplies during shortages, public health emergencies, natural disasters, or CBRN threats. The Secretary must publish the covered drug/API list and issue guidance within 180 days on how vulnerabilities and eligible entities are identified and how the program will operate.